Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT-100 in Duchenne Muscular Dystrophy
NCT01847573Phase 2Terminated
- Sponsor
- Processa Pharmaceuticals, Inc.
- Start
- May 2013
- Primary completion
- Mar 2016
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of halofuginone in Duchenne muscular dystrophy (DMD) (6 cohorts), sponsored by Processa Pharmaceuticals, Inc. Primary endpoint: Safety and tolerability of administering single and multiple ascending doses of HT-100 at 1 week. Started May 2013; status: terminated.
02
Drugs
halofuginone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01847573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01847573.